New drug combo targets Hard-to-Treat lung cancer
NCT ID NCT04250545
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing two oral drugs, Sapanisertib and Telaglenastat, in 22 people with advanced non-small cell lung cancer that has spread to the brain or other organs. The drugs work by blocking key enzymes that cancer cells need to grow. The main goal is to find the safest dose and check for any early signs that the combination might shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sapanisertib and Telaglenastat (two oral drugs that block enzymes needed for cancer cell growth)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with advanced non-small cell lung cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 22 participants, so the main goal is safety and dosing, not yet proving the drugs work. The combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
City of Hope at Irvine Lennar
Irvine, California, 92618, United States
-
Keck Medicine of USC Koreatown
Los Angeles, California, 90020, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States